BRUNEI

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates

Retrieved on: 
Friday, March 29, 2024
CPS, Patient, Lung cancer, IND, Infection, Cancer, Investment, Cisplatin, Paclitaxel, Melanoma, Marketing, RNA, New chemical entity, Gentlemen's agreement, NRDL, Food, Therapeutic Goods Administration, Biologics license application, Insurance, Research, Junshi, National Medical Products Administration, TGA, FDA, NMPA, Tablet, COVID-19, NPC, Spacecraft, DSM-IV codes, Dacarbazine, Axitinib, Total, Pharmaceutical industry

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates.

Key Points: 
  • SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates.
  • Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022.
  • Loss attributable to owners was RMB2,282 million in 2023, representing a decrease of RMB104 million compared to the previous year.
  • This application was later approved for marketing in December 2023, marking the first and only approved perioperative therapy for lung cancer domestically.

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 28, 2024
AstraZeneca, Exercise, Fortification, New Drug Application, Patient, GBM, CRL, NDA, Menkes, Minocycline, Therapy, Marketing, Radiation, CKPT, Rosacea, Investigational New Drug, Erythema, Safety, BLA, Fortress Biotech, Food, Red, Amyloidosis, Dermatology, Carcinoma, FDA, Hyperhidrosis, Mustang Bio, Menkes disease, PDUFA, Pharmaceutical industry

MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Key Points: 
  • Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “In 2023, we built a significant amount of momentum to position our Company to achieve multiple milestones in 2024.
  • In March 2024, the FDA accepted the NDA and has set a PDUFA goal date of November 4, 2024.
  • In December 2023, the FDA issued a complete response letter (“CRL”) for the cosibelimab BLA.
  • Fortress’ consolidated net revenue totaled $84.5 million for the full year ended December 31, 2023, which included $59.7 million in net revenue generated from our marketed dermatology products.

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 21, 2024
Research, U.S. FDA, Conference, Growth, Journey, Agreement, FY, IGA, Microbiota, Risk, New Drug Application, Patient, Food and Drug Administration, Rosacea, Hyperhidrosis, NDA, Red, News, Adjustment, Dermatology, Clinical trial, Erythema, Doxycycline, Safety, GAAP, Food, Marketing, FDA, CEA, Total, PDUFA, Pharmaceutical industry

SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.

Key Points: 
  • ET to discuss the financial results and provide a business update
    SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.
  • Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “2023 was a year of growth and development for Journey Medical.
  • In December 2023, Journey Medical entered into a $20.0 million credit facility with SWK Holdings Corporation (“SWK”), a specialized finance company with a focus on the global healthcare sector.
  • In July 2023, Journey Medical announced positive topline results from the two DFD-29 Phase 3 clinical trials (MVOR-1 & MVOR-2) for the treatment of rosacea.

Digital Redemption Unlocked: Choice Privileges Makes It Easier for Members to Use Points for Luxury Stays at Preferred Hotels & Resorts

Retrieved on: 
Tuesday, April 2, 2024
Preferred Hotels & Resorts, Pub, Hotel, Partnership, Choice Hotels, Comfort, Palms Casino Resort, Radisson Hotel Group, CHH, Marketing, Sleep

NORTH BETHESDA, Md., April 2, 2024 /PRNewswire/ -- Choice Privileges, the award-winning rewards program of Choice Hotels International, Inc. (NYSE: CHH) has made it easier to book redemption stays at more than 300 Preferred Hotels & Resorts properties by enabling digital redemption on ChoiceHotels.com. Redemption levels begin at 25,000 Choice Privileges points per night for stays at hotels including The Palms Hotel & Spa (Miami Beach, Florida), Half Moon (Montego Bay, Jamaica), Gayana Marine Resort (Kota Kinabalu, Malaysia), The Empire Brunei (Bandar Seri Begawan, Brunei) and Le Belmont Paris (Paris, France).

Key Points: 
  • Currently, to book, Choice Privileges members sign into their Choice Privileges accounts on ChoiceHotels.com and navigate to the Preferred Hotels & Resorts landing page.
  • Points will be removed from members' Choice Privileges accounts when a hotel is booked, and members will receive a confirmation summary from Preferred Hotels & Resorts.
  • Earning Choice Privileges Points is Easy:
    Choice Privileges offers members many ways to earn points that can be used for redemption stays including at Preferred Hotels & Resorts.
  • Members can also earn points through two co-brand credit cards – the Choice Privileges Select Mastercard and Choice Privileges Mastercard.

Oceania Cruises Offers Free Pre-Cruise Hotel Stay on a Range of Sailings in 2024 and 2025

Retrieved on: 
Tuesday, March 26, 2024
Spend, Culture, Ginza, Boulders Beach, Travel, City, Atlantic Ocean, Boat racing, Tourism

MIAMI, March 26, 2024 /PRNewswire/ -- Oceania Cruises, the world's leading culinary- and destination-focused cruise line, has announced that it will offer guests a free pre-cruise hotel stay on a range of sailings throughout late 2024 and 2025. The offer means that curious travelers will have the convenience of arriving a day before their cruise embarkation as well as the opportunity to delve even further into the departure port on their itinerary before relaxing in the comfort of Oceania Cruises' small, luxurious ships.

Key Points: 
  • MIAMI, March 26, 2024 /PRNewswire/ -- Oceania Cruises , the world's leading culinary- and destination-focused cruise line, has announced that it will offer guests a free pre-cruise hotel stay on a range of sailings throughout late 2024 and 2025.
  • The offer is available for reservations made between April 1, 2024, and May 31, 2024, giving guests ample time to choose their next bucket-list cruise.
  • With this generous offer, travelers can start their cruise vacation with an extra measure of comfort and ease.
  • For additional information on Oceania Cruises' small-ship luxury product, exquisitely crafted cuisine, and expertly curated travel experiences, visit OceaniaCruises.com , call 855-OCEANIA, or speak with a professional travel advisor.

Capital A International, Owner of the Iconic AirAsia Brand, to be Publicly Listed in the U.S. through Business Combination with Aetherium Acquisition Corp

Retrieved on: 
Wednesday, February 28, 2024
Air, Transport, Transportation, Vacation, Destinations, Travel, Social media, Aircraft, Air travel, CAPI, Aviation, Growth, European, Business analyst, Fintech, Intellectual property, LLP, Kuala Lumpur Stock Exchange, Capital, Partner, Airline

CAPI leverages the expansion, management and licensing of the AirAsia brand, and serves as a dynamic global marketing catalyst for Asean brands.

Key Points: 
  • CAPI leverages the expansion, management and licensing of the AirAsia brand, and serves as a dynamic global marketing catalyst for Asean brands.
  • Tony Fernandes, Chief Executive Officer of Capital A said, “Over more than two decades, AirAsia has become a prestigious brand synonymous with value, innovation and inclusivity.
  • The evolution of the AirAsia brand has created a loyal global consumer base, positioning us favorably to expand our brand internationally through CAPI.
  • Under the terms of the proposed transaction, CAPI will combine with Aetherium and become a publicly traded entity.

NACIFIC Announce Debut ATEEZ Special Collaboration Product Launch

Retrieved on: 
Friday, February 16, 2024
Handwriting, Name, Light, Allantoin, Hand, Marketing, ID, Perfume, Hong Kong Technology Venture, KST, Lip, CIS, ATEEZ, Cosmetics

Additionally, the event has a special feature of incorporating the members' signatures and handwriting, enhancing the uniqueness of the collaboration.

Key Points: 
  • Additionally, the event has a special feature of incorporating the members' signatures and handwriting, enhancing the uniqueness of the collaboration.
  • Moreover, the ATEEZ Special Edition, comprising eight fragrance names inspired by the members' birth flowers, adds significance to the collaboration.
  • In the 'Shine Mood Slick' Special Edition as well, the colors are inspired by the moods of the ATEEZ members.
  • Meanwhile, NACIFIC will host an event marking its first collaboration with ATEEZ starting from February 20th at 11:00AM(KST).

Euronet Announces Acquisition of Infinitium, a Leading Digital Payments Company in Southeast Asia

Retrieved on: 
Tuesday, February 13, 2024
Software, Acquisition, 3-D Secure, Senior, Risk management, Growth, Fraud, Risk, Ren, European, Ecosystem, CNP, E-commerce, Workforce, Online shopping

LEAWOOD, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Euronet (NASDAQ: EEFT), a leading global financial technology solutions and payments provider, today announced the acquisition of Infinitium Holdings Pte.

Key Points: 
  • LEAWOOD, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Euronet (NASDAQ: EEFT), a leading global financial technology solutions and payments provider, today announced the acquisition of Infinitium Holdings Pte.
  • Ltd (Infinitium), a digital payments company and provider of risk management and payments authentication services based in Singapore.
  • Infinitium’s products will be integrated with Euronet’s Ren payments platform to provide additional protection against consumer fraud and merchant chargebacks in online transactions.
  • This authentication step adds an extra level of security, reducing the risk of unauthorized transactions and enhancing overall online payment security.

Weatherford Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 6, 2024
Well, Carbon, Petrobras, Partnership, ExxonMobil, Growth, Weatherford International, Senior, WFRD, PTTEP, Ageing, Note, QatarEnergy, Safety, Capital, MPD, Capital expenditure, Pump, CCS, Well services, Acquisition, Video game

HOUSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Weatherford International plc (NASDAQ: WFRD) (“Weatherford” or the “Company”) announced today its results for the fourth quarter of 2023 and full year 2023.

Key Points: 
  • Operating income was $216 million in the fourth quarter of 2023, compared to $218 million in the third quarter of 2023 and $169 million in the fourth quarter of 2022.
  • Basic income per share was $1.94, compared to $1.70 in the third quarter of 2023 and $1.01 in the fourth quarter of 2022.
  • Fourth quarter 2023 cash flows provided by operating activities were $375 million, compared to $172 million in the third quarter of 2023 and $193 million in the fourth quarter of 2022.
  • Capital expenditures were $67 million in the fourth quarter of 2023, compared to $42 million in the third quarter of 2023 and $49 million in the fourth quarter of 2022.

Wintermar Offshore (WINS:JK) Invests in Bruneian Company for Offshore Supply Vessel Operations

Retrieved on: 
Friday, February 2, 2024
Partnership, JK, WINS

JAKARTA, Feb 2, 2024 - (ACN Newswire) - On January 30, 2024, PT Wintermar Offshore Marine Tbk (WINS:JK) entered a strategic venture through a 49% stake in SAVWIN Sdn Bhd with a Brunei-based partner.

Key Points: 
  • JAKARTA, Feb 2, 2024 - (ACN Newswire) - On January 30, 2024, PT Wintermar Offshore Marine Tbk (WINS:JK) entered a strategic venture through a 49% stake in SAVWIN Sdn Bhd with a Brunei-based partner.
  • Through this partnership, Wintermar will have an advantage in tendering for longer term contracts in Brunei which favour local content.
  • Savwin Sdn Bhd will initially operate a Fast Multi-Purpose Supply Vessel which is currently on a long term contract in Brunei until 2027.
  • Wintermar group's 4Q2023 fleet utilization reached 74%, which was better than 70% recorded in 3Q2023.